VentriPoint Diagnostics (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) announces

it has completed the validation test, which compared the VentriPoint

Medical System (VMS) to cardiac Magnetic Resonance Imaging (MRI) in

patients with Pulmonary Arterial Hypertension (PAH).

"This a world's first - accurate cardiac information with the

convenience and speed of 2-D ultrasound", stated Dr. George Adams,

VentriPoint President and CEO. "The Company will begin sales efforts

for the PAH application in Europe and Canada as soon as regulatory

approvals are received, which should be in the second calendar quarter

this year."

The company will immediately begin to write the submission to the

European Notified Body and Health Canada to extend its already

received approvals to include PAH. A multicenter clinical trial in the

United States has been in planning for many months and will now be

initiated. As a first step, VentriPoint will install the VMS at each

centre and train the sonographers and cardiologists. An announcement

of the complete study design and the participants will be made as soon

as contractual arrangements have been finalized.

The VMS is for investigational use only in the United States and is

approved for clinical use in Canada and Europe.

About Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is the most serious form of the

five recognized groups of pulmonary hypertension. PAH is a devastating

disease with an average patient lifespan of less than 3 years after

diagnosis if untreated. It affects individuals of all ages from

infancy to the elderly. Although treatment started early after

detection appears more effective than when started later, the majority

of patients with PAH continue to be diagnosed too late for treatment

to be fully effective. PAH can occur for no known reason but will

typically occur in association with many common conditions such as

chronic liver disease and liver cirrhosis; connective tissue disorders

such as scleroderma or systemic lupus erythematosus (lupus);

congenital heart disease (even if repaired) and HIV. With increasing

availability of effective therapies, and evidence-based treatment

guidelines recommending starting treatment early, tests enabling

detection as early as possible should prove invaluable.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor

patients with heart disease, a leading cause of death in developed

countries. The VMS is the first cost-effective and accurate

diagnostic tool for measuring right ventricle heart function.

Monitoring congenital heart disease is the first application in a

suite of applications for all major heart diseases including pulmonary

hypertension, cardiovascular disease and heart failure - a

multibillion-dollar market potential. Canada and Europe (CE Mark) have

granted approval for the sale of VentriPoint's VMS heart analysis

system and VentriPoint is pursuing US-FDA approval through the 510(k)


FORWARD-LOOKING STATEMENTS: The statements made in this press release

that are not historical facts contain forward-looking information that

involves risk and uncertainties. All statements, other than statements

of historical facts, which address VentriPoint's expectations, should

be considered forward-looking statements. Such statements are based on

management's exercise of business judgment as well as assumptions made

by and information currently available to management. When used in

this document, the words "may", "will", "anticipate", "believe",

"estimate", "expect", "intend" and words of similar import, are

intended to identify any forward-looking statements. You should not

place undue reliance on these forward-looking statements. These

statements reflect a current view of future events and are subject to

certain risks and uncertainties as contained in the Corporation's

filings with Canadian securities regulatory authorities. Should one or

more of these risks or uncertainties materialize, or should underlying

assumptions prove incorrect, actual results could differ materially

from those anticipated in these forward-looking statements. The

Corporation undertakes no obligation, and does not intend, to update,

revise or otherwise publicly release any revisions to these

forward-looking statements to reflect events or circumstances after

the date hereof, or to reflect the occurrence of any unanticipated

events. Although management believes that expectations are based on

reasonable assumptions, no assurance can be given that these

expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release